Evaluation of the efficacy and safety of methylprednisolone pulse therapy in treatment of Covid-19 patients with Acute respiratory distress syndrome

INTERVENTION: Intervention 1: Intervention group: Patients hospitalized with COVID‐19 disease who in addition to their standard treatment ( Hydroxychloroquine 400mg daily) will be received 1000mg/day Methylprednisolone? for 3 days. Intervention 2: Control group: Patients hospitalized with COVID‐19 disease who are received standard treatment ( Hydroxychloroquine 400mg daily). CONDITION: COVID‐19 Disease. ; COVID‐19 U07.2, PRIMARY OUTCOME: Blood O2 saturation. Timepoint: before and during the study for 14 days. Method of measurement: pulse Oximeter. Mortality rate. Timepoint: from including to study to 60 days. Method of measurement: observation. Oxygen therapy need. Timepoint: before and during the study for 14 days. Method of measurement: Clinical. SECONDARY OUTCOME: Chest CT Scan changes 48 hours after starting pulse therapy. Timepoint: 48 hours after starting methylprednisolon pulse therapy. Method of measurement: Chest CT Scan. ICU length of stay. Timepoint: During the study until ICU discharge. Method of measurement: Patients file. Sequential Organ Failure Assessment (SOFA) Score changes. Timepoint: before and during the study. Method of measurement: clinical. INCLUSION CRITERIA: Patient with moderate to severe Covid‐19 admitted to ICU PaO2/FiO2 Less than 300 Progression of disease severity and not responding to standard treatment prediction of intubation for next 24 hours